These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 16240208

  • 1. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux disease.
    Kahrilas PJ, Miner P, Johanson J, Mao L, Jokubaitis L, Sloan S.
    Dig Dis Sci; 2005 Nov; 50(11):2009-18. PubMed ID: 16240208
    [Abstract] [Full Text] [Related]

  • 2. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial.
    Miner P, Orr W, Filippone J, Jokubaitis L, Sloan S.
    Am J Gastroenterol; 2002 Jun; 97(6):1332-9. PubMed ID: 12094846
    [Abstract] [Full Text] [Related]

  • 3. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F, Annese V, Prada A, Zambelli A, Casalini S, Nardini P, Bianchi Porro G, Italian Rabeprazole Study Group.
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [Abstract] [Full Text] [Related]

  • 4. Rabeprazole-based therapy in the management of symptomatic gastroesophageal reflux disease.
    Sloan S.
    Am J Gastroenterol; 2003 Mar; 98(3 Suppl):S49-55. PubMed ID: 12644031
    [Abstract] [Full Text] [Related]

  • 5. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L, FAST Trial Investigators.
    Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
    [Abstract] [Full Text] [Related]

  • 6. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
    Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL.
    Aliment Pharmacol Ther; 2002 Mar; 16(3):479-85. PubMed ID: 11876701
    [Abstract] [Full Text] [Related]

  • 7. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A, Wruble LD, Humphries TJ.
    Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
    [Abstract] [Full Text] [Related]

  • 8. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
    Bytzer P, Morocutti A, Kennerly P, Ravic M, Miller N, ROSE Trial Investigators.
    Scand J Gastroenterol; 2006 Oct; 41(10):1132-40. PubMed ID: 16990197
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J, van Rensburg C, Vieweg W, Fischer R.
    Digestion; 2004 Oct; 70(1):61-9. PubMed ID: 15297779
    [Abstract] [Full Text] [Related]

  • 10. Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.
    Bytzer P, Blum A, De Herdt D, Dubois D, Trial Investigators.
    Aliment Pharmacol Ther; 2004 Jul 15; 20(2):181-8. PubMed ID: 15233698
    [Abstract] [Full Text] [Related]

  • 11. Reductions in symptom distress reported by patients with moderately severe, nonerosive gastroesophageal reflux disease treated with rabeprazole.
    Damiano A, Siddique R, Xu X, Johanson J, Sloan S.
    Dig Dis Sci; 2003 Apr 15; 48(4):657-62. PubMed ID: 12741452
    [Abstract] [Full Text] [Related]

  • 12. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ.
    Aliment Pharmacol Ther; 1999 Jan 15; 13(1):49-57. PubMed ID: 9892879
    [Abstract] [Full Text] [Related]

  • 13. [Assessment of efficacy and safety of two modes of maintenance therapy with rabeprazole in patients with gastroesophageal reflux disease (GERD) of degrees 0 and 1].
    Minushkin ON, Maslovskiĭ LV, Anikina NIu, Shuleshova AG.
    Eksp Klin Gastroenterol; 2005 Jan 15; (2):29-35. PubMed ID: 15932152
    [No Abstract] [Full Text] [Related]

  • 14. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A, Breiter J, Perdomo C, Barth J.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):193-202. PubMed ID: 16091056
    [Abstract] [Full Text] [Related]

  • 15. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease.
    Delchier JC, Cohen G, Humphries TJ.
    Scand J Gastroenterol; 2000 Dec 01; 35(12):1245-50. PubMed ID: 11199361
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
    Richter JE, Peura D, Benjamin SB, Joelsson B, Whipple J.
    Arch Intern Med; 2000 Jun 26; 160(12):1810-6. PubMed ID: 10871975
    [Abstract] [Full Text] [Related]

  • 17. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
    Archimandritis AJ, Nikolopoulou V, Kouklakis G, Paraskevas E, Avgerinos A, Tsianos E, Triantafillidis JK, Hellenic Rabeprazole Study Group.
    Curr Med Res Opin; 2005 Apr 26; 21(4):603-10. PubMed ID: 15899110
    [Abstract] [Full Text] [Related]

  • 18. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J, Dodd S, Durkin M, Sloan S.
    Manag Care; 2002 Jul 26; 11(7 Suppl):14-8. PubMed ID: 12181872
    [Abstract] [Full Text] [Related]

  • 19. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease.
    Tolia V, Bishop PR, Tsou VM, Gremse D, Soffer EF, Comer GM, Members of the 322 Study Group.
    J Pediatr Gastroenterol Nutr; 2006 Apr 26; 42(4):384-91. PubMed ID: 16641576
    [Abstract] [Full Text] [Related]

  • 20. Clinical trial: maintenance intermittent therapy with rabeprazole 20 mg in patients with symptomatic gastro-oesophageal reflux disease - a double-blind, placebo-controlled, randomized study.
    Fass R, Delemos B, Nazareno L, Kao R, Xiang J, Lu Y.
    Aliment Pharmacol Ther; 2010 May 26; 31(9):950-60. PubMed ID: 20132154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.